"Postmenopause" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The physiological period following the MENOPAUSE, the permanent cessation of the menstrual life.
| Descriptor ID |
D017698
|
| MeSH Number(s) |
G08.686.157.500.625 G08.686.841.249.500.625
|
| Concept/Terms |
Postmenopause- Postmenopause
- Postmenopausal Period
- Period, Postmenopausal
- Post-Menopause
- Post Menopause
- Post-Menopauses
- Post-menopausal Period
- Period, Post-menopausal
- Post menopausal Period
|
Below are MeSH descriptors whose meaning is more general than "Postmenopause".
Below are MeSH descriptors whose meaning is more specific than "Postmenopause".
This graph shows the total number of publications written about "Postmenopause" by people in this website by year, and whether "Postmenopause" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 5 | 0 | 5 |
| 1995 | 0 | 3 | 3 |
| 1996 | 1 | 1 | 2 |
| 1997 | 2 | 4 | 6 |
| 1998 | 3 | 5 | 8 |
| 1999 | 2 | 7 | 9 |
| 2000 | 1 | 5 | 6 |
| 2001 | 1 | 5 | 6 |
| 2002 | 0 | 6 | 6 |
| 2003 | 2 | 16 | 18 |
| 2004 | 1 | 11 | 12 |
| 2005 | 4 | 11 | 15 |
| 2006 | 2 | 3 | 5 |
| 2007 | 4 | 4 | 8 |
| 2008 | 2 | 12 | 14 |
| 2009 | 4 | 9 | 13 |
| 2010 | 4 | 11 | 15 |
| 2011 | 2 | 8 | 10 |
| 2012 | 1 | 9 | 10 |
| 2013 | 7 | 9 | 16 |
| 2014 | 6 | 7 | 13 |
| 2015 | 6 | 7 | 13 |
| 2016 | 2 | 9 | 11 |
| 2017 | 5 | 7 | 12 |
| 2018 | 3 | 3 | 6 |
| 2019 | 3 | 3 | 6 |
| 2020 | 1 | 5 | 6 |
| 2021 | 3 | 3 | 6 |
| 2022 | 1 | 2 | 3 |
| 2023 | 0 | 9 | 9 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Postmenopause" by people in Profiles.
-
Real-World Implications of the SOUND Trial. Ann Surg Oncol. 2024 Dec; 31(13):8776-8785.
-
Does Urodynamic Stress Incontinence Increase After the Menopause?: Results from 2,994 Urodynamic Studies in Australian Women. Int Urogynecol J. 2024 Sep; 35(9):1789-1796.
-
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Mar 01; 10(3):362-371.
-
Tumor-Associated and Systemic Autoimmunity in Pre-Clinical Breast Cancer among Post-Menopausal Women. Biomolecules. 2023 10 24; 13(11).
-
Post-Menopausal Bleeding: Role of Imaging. Semin Ultrasound CT MR. 2023 Dec; 44(6):519-527.
-
Racial Disparities in Locoregional Recurrence in Postmenopausal Patients with Stage I-III, Hormone Receptor-Positive Breast Cancer Enrolled in the NSABP B-42 Clinical Trial. Ann Surg Oncol. 2023 Dec; 30(13):8320-8326.
-
To Dissect or Not to Dissect: Can We Predict the Presence of Four or More Axillary Lymph Node Metastases in Postmenopausal Women with Clinically Node-Negative Breast Cancer? Ann Surg Oncol. 2023 Dec; 30(13):8327-8334.
-
Site specific differences in vBMD and geometry in postmenopausal women with primary hyperparathyroidism. Endocrine. 2024 Jan; 83(1):205-213.
-
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2023 05 01; 9(5):664-672.
-
Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA. Pharmacoeconomics. 2023 06; 41(6):709-718.